skip to Main Content

2018 TAG Update

I want to thank all of you for the support that enabled the successes TAG achieved this past year. Despite a challenging political climate and continued attacks against those living with or at risk of contracting HIV, tuberculosis (TB), or…

Read more

Right to Science Submission – October, 2018

The right to enjoy the benefits of scientific progress and its applications is a fundamental human right and one of the central pillars of TAG's advocacy to promote TB research and access to its benefits. The right is enshrined in Article 27 of the Universal Declaration of Human Rights and further articulated in Article 15 of the International Covenant on Economic, Social, and Cultural Rights (ICESCR).
Read more

The HCV Diagnostics Pipeline

July 2018 by Bryn Gay Simpler Rapid, Point-of-Care Hepatitis C Diagnostics: Are We There Yet?1 To increase treatment rates and make a dent in the epidemic by 2030, countries need to scale up access to affordable, simple, rapid diagnostics, ensuring…

Read more

The HCV Treatment Pipeline

July 2018 Annette Gaudino HCV TREATMENT PIPELINE: THE DEFERRED DREAM OF TREATMENT FOR ALL Generic combinations of direct-acting antivirals (DAAs), including sofosbuvir/daclatasvir show bioequivalence compared to originators with equivalent sustained virological responses (SVR). Both sofosbuvir/daclatasvir and sofosbuvir/ravidasvir demonstrate SVR rates…

Read more

White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications

Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Read more

TAGline Spring 2018

Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.
Read more
Back To Top